The Interministerial Commission for Strategic Investments on Wednesday approved a new strategic investment by ELPEN SA, a Greek pharmaceutical company, worth 51 million euros, which envisages the creation of 75 new job positions.
ELPEN’s investment plan covers the planning and development of a vertical activity in research-development-production-promotion of new added value pMDIs to be used for the cure of acute and chronic problems of the respiratory system.
Under the investment plan, ELPEN will build a new factory in Keratea, along with the construction of a new experimental laboratory in Spata, both in eastern Attica.
